Our Take
Genetics matter for anxiety risk, but environment matters far more—and the study proves it by showing genetics accounts for just 6% of symptom severity variation.
Why it matters
Anxiety rates are climbing globally, especially in young adults. Understanding which people carry genetic sensitivity to environmental triggers could shift prevention and treatment from one-size-fits-all to targeted strategies, but only if clinicians pair genetic screening with environmental interventions.
Do this week
Psychiatrists and mental health researchers: review the Nature Human Behaviour findings against your current anxiety assessment protocols this week to identify whether genetic risk profiling improves patient stratification for your population.
Researchers identify 74 genetic sites tied to anxiety severity
A genome-wide association study (GWAS) led by King's College London and QIMR Berghofer Medical Research Institute analyzed genetic data from 693,869 people of European ancestry and found 74 genome locations where genetic differences correlate with anxiety symptom severity. The study, published in Nature Human Behaviour, identified 39 previously unknown associations.
The work differs from prior anxiety genetics studies by linking genetic variants to the severity of symptoms along a continuum, rather than classifying people as having or not having an anxiety diagnosis. This approach reveals how anxiety risk operates as a spectrum from healthy stress responses to debilitating disorder.
Specific genes implicated include PCLO and SORCS3, both highly active in brain tissue and involved in nerve cell communication. The breadth of findings suggests multiple biological pathways contribute to anxiety risk (per the research team).
The study also found genetic correlations between anxiety and other conditions, including depression, irritable bowel syndrome, chronic pain, coronary artery disease, endometriosis, and migraine.
Genetics explain only 6% of the variation—environment is the lever
Common genetic variation accounts for roughly 6% of differences in anxiety symptom severity between individuals (company-reported). That leaves 94% attributable to environmental factors, gene-environment interactions, and undetected genetic effects.
This finding inverts the common assumption about anxiety etiology. Megan Skelton, first author at King's College London, stated in the study that rising anxiety rates point to environmental factors because genetics do not change substantially across generations. One person with high genetic risk may never develop anxiety; another with low genetic risk could develop severe symptoms.
The implication is direct: reducing population-level anxiety requires addressing environmental and social drivers. Genetics can identify who is more sensitive to those drivers, enabling targeted prevention. But genetics alone cannot explain or resolve the epidemic.
How clinicians can use the findings
Understanding genetic risk architecture helps identify individuals more vulnerable to environmental stressors. Thalia Eley, lead author and professor of developmental behavioral genetics at King's College London, noted that progress in anxiety genetics has lagged behind other major mental health conditions despite anxiety's high public health burden.
Clinicians now have a larger catalog of genetic markers to profile patients. The next step requires clinical validation: testing whether genetic risk scores improve patient stratification, treatment selection, or early intervention outcomes in practice. Standalone genetic screening without environmental and psychological assessment will not reduce anxiety.
The researchers called for large-scale follow-up analyses to deepen understanding of anxiety's genetic architecture and to move beyond European ancestry populations, which dominate GWAS databases.